Phase 1 and Dose Expansion Study of APR-246 in Combination with Acalabrutinib or Venetoclax-based therapy in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
MD Anderson Study Status
APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT, APR-246 (eprenetapopt) + Venetoclax + Rituximab in RT
Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.